ERBB2 and gastroesophageal junction adenocarcinoma: In particular, Disitamab vedotin has been approved by the National Medical Products Administration (NMPA) for the second-line and above treatment of patients with HER2-overexpressing advanced metastatic G/GEJ adenocarcinoma.